This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities
Journal of Nanobiotechnology Open Access 03 December 2022
-
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Molecular Neurodegeneration Open Access 08 November 2022
-
Granulocyte-colony stimulating factor gene therapy as a novel therapeutics for stroke in a mouse model
Journal of Biomedical Science Open Access 30 October 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smalley, E. First AAV gene therapy poised for landmark approval. Nat Biotechnol 35, 998–999 (2017). https://doi.org/10.1038/nbt1117-998
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1117-998
This article is cited by
-
Non-viral delivery of nucleic acid for treatment of rare diseases of the muscle
Journal of Biosciences (2024)
-
Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
Gene Therapy (2023)
-
Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice
Gene Therapy (2023)
-
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Molecular Neurodegeneration (2022)
-
Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities
Journal of Nanobiotechnology (2022)